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Modelling of combination therapy 
using implantable anticancer drug 
delivery with thermal ablation 
in solid tumor
Muneer Al‑Zu’bi  & Ananda Mohan *
Local implantable drug delivery system (IDDS) can be used as an effective adjunctive therapy for 
solid tumor following thermal ablation for destroying the residual cancer cells and preventing 
the tumor recurrence. In this paper, we develop comprehensive mathematical pharmacokinetic/
pharmacodynamic (PK/PD) models for combination therapy using implantable drug delivery system 
following thermal ablation inside solid tumors with the help of molecular communication paradigm. 
In this model, doxorubicin (DOX)‑loaded implant (act as a transmitter) is assumed to be inserted 
inside solid tumor (acts as a channel) after thermal ablation. Using this model, we can predict the 
extracellular and intracellular concentration of both free and bound drugs. Also, Impact of the 
anticancer drug on both cancer and normal cells is evaluated using a pharmacodynamic (PD) model 
that depends on both the spatiotemporal intracellular concentration as well as characteristics of 
anticancer drug and cells. Accuracy and validity of the proposed drug transport model is verified with 
published experimental data in the literature. The results show that this combination therapy results 
in high therapeutic efficacy with negligible toxicity effect on the normal tissue. The proposed model 
can help in optimize development of this combination treatment for solid tumors, particularly, the 
design parameters of the implant.
Cancer is one of the most dangerous and deadliest diseases that cause deaths of millions of people around the 
world each year. More than 85% of human cancers appear as solid  tumors1. Minimally invasive and image-
guided thermal ablation techniques such as radiofrequency ablation (RFA) and high-intensity focused ultrasound 
(HIFU) ablation have been used for local treatment of malignant solid tumors as an alternative for systemic 
chemotherapy and surgical  resection2. In thermal ablation, the tissue temperature rises above 50 °C, which is 
enough to destroy tumor tissue by inducing coagulation  necrosis2. Thus, thermal ablation will destroy the cel-
lular and vasculature structures, which results in a new ablated tissue with different characteristics. However, 
the main limitation and challenge of thermal ablation is the risk of local recurrence and residual tumor after the 
thermal ablation, particularly at the tumor  periphery3–5. The experimental studies showed that the combination 
therapy through local release of anticancer drugs from a miniaturized implant in solid tumors following thermal 
ablation can result in a better therapeutic efficacy by destroying the residual cancer cells and preventing tumor 
 recurrence6–8.
Anticancer drug distribution and fluid flow within solid tumors are essential factors that affect the clinical 
efficiency of anticancer therapies. In addition to that, pharmacokinetic processes, including drug efflux/influx 
into cells, drug binding/unbinding with interstitial proteins, perfusion into blood capillaries, and biodegrada-
tion, have a significant impact on the therapeutic outcomes. Moreover, one of the most important challenges in 
the development of new drug delivery systems (DDSs) is ensuring that the optimal amount of drug is achieved 
in tumor versus normal tissues to avoid toxicity in the healthy tissues. Dual-release implants have been clini-
cally approved and currently used for cancer treatments in the clinical trials and research, e.g., Gliadel polymer 
 implants9. The implant releases the anticancer drug over two phases, namely, burst and sustained releases. For 
example, in-situ forming implants (ISFIs) have a dual-release pattern with a large undesirable burst release, 
which may cause major toxicity problems and consume the loaded drug in the implants  rapidly10. Designing 
this type of implants with a minimum initial burst release becomes an attractive challenge, and one of the key 
issues in the design of  ISFIs11. Moreover, some drug-loaded implants can be designed in a controlled way to 
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have a dual-release profile to release a large amount of drug early, i.e., burst release, to rapidly reach the effective 
therapeutic concentration at the target site while keeping drug concentration within the effective level during 
the sustained release  phase12. Therefore, providing mathematical pharmacodynamic (PD) and pharmacokinetic 
(PK) models to examine and analyze the impact of the anticancer drug on the surrounding healthy and tumor 
tissues is necessary for design the implantable DDSs to get high therapeutic efficiency.
Mathematical and computational modelling of release and transport of anticancer drugs have played a vital 
role in the advancement of drug delivery systems. These models provide a powerful tool for understanding drug 
transport and other complex pharmacokinetics processes and their impact on the tumor cells and the surround-
ing tissues (pharmacodynamics). As a result, they can help in optimum design and development of the DDSs to 
reduce the number of animal experiments which save time and reduce cost. A comprehensive review of litera-
ture has been discussed on mathematical models that have been employed to improve and design anti-cancer 
 DDSs13–15. For example, mathematical models were used to aid the design and optimization of doxorubicin-
loaded liposome formulations to achieve a better therapeutic index in  tumor16. Application of mathematical mod-
eling to guide the development of various drug delivery systems, e.g., extended-release formulation, liposome, 
etc., was  presented17. These models optimized the drug formulation and dose regimen, accelerated the clinical 
trial, evaluated the influence of the drug on anti-tumor efficacy, predicted the clinical response by preclinical 
data, etc. A generic model is developed to minimize the number of suppositions about drug distribution to 
describe the behavior of therapeutic and diagnostic drugs in tumor  environments18. Furthermore, a mathemati-
cal model is developed to study the effect of the various factors on the delivery of BCNU chemotherapy to brain 
tumor using systemic administration and local release from Gliadel  wafer19. This model yields information on 
the optimal polymer implant location and the efficacy of controlled drug delivery by Gliadel wafer compared to 
traditional degradable polymers.
Most of the mathematical works on anticancer drug transport are limited to systemic drug delivery while few 
simplified models on implantable drug delivery systems (IDDSs) following thermal ablation are  reported12,20,21. 
A mathematical model was derived at steady-state for design dual-release doxorubicin (DOX)-loaded implant 
to provide the optimal drug pharmacokinetics at the tumor ablation boundary after  RFA12. A numerical model 
was proposed to estimate the DOX drug transport parameters, e.g., diffusivity and elimination rate, following 
insertion of a dual-release implant in liver tissues with/without  RFA22. A computational transport model was 
proposed for simulation and prediction transport and pharmacokinetics of DOX after inserting biodegradable 
implants in liver tumors following  RFA20,21,23. However, the models discussed above are derived based on many 
simplified assumptions, such as taking the impact of pharmacokinetics (e.g., elimination, cellular uptake/efflux, 
and binding) as an average equilibrium process via an effective rate constant. These models do not characterize 
and predict the dynamic intracellular concentration of anticancer drugs and the binding of anticancer drugs 
with proteins in the tissue. Furthermore, the works mentioned above do not provide any pharmacodynamic 
model which can be used for evaluating the therapeutic efficacy, i.e., the impact of the anticancer drug on tumor 
and healthy tissues.
In this paper, we develop a comprehensive mathematical and computational model for local release and 
transport of anticancer DOX drug following insertion of a dual-release implant inside a thermally ablated solid 
tumor with the help of molecular communication (MC) abstraction, see Fig. 1. We chose DOX anticancer drug 
because it is widely used in chemotherapy due to its efficacy in killing a wide range of cancers such as carcinomas, 
sarcomas, and hematological  cancers24. Moreover, there are many experimental measured parameters for DOX 
in the literature which can be used in our models to get more accurate results. However, the proposed model can 
be applied to other drugs by adjusting the drug parameters in the model. Molecular communication is an emerg-
ing paradigm for exchange the biochemical molecules between the biological cells and synthetic nanomachines 
within the biological aqueous  environments25,26. One of the most important applications of the MC paradigm is 
modelling and abstraction of the drug delivery systems, particularly for providing the drug at the site of action 
and minimizing the drug in the healthy  tissues25,26. In this paradigm, the drug delivery process is abstracted as 
a communication mechanism, as shown in Fig. 2. The implantable drug delivery device (the implant) acts as 
a transmitter while the target site, i.e., malignant cell, acts as a receiver. The anticancer therapeutic agent, i.e., 
DOX, can be considered as information molecules. The tumor microenvironment is a three-dimensional (3-D) 
Figure 1.  Graphical illustration of the drug implant inserted in 3-D solid tumor.
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medium surrounded by normal tissue, which acts as a molecular communication channel. At the target sites, the 
intracellular concentration of the anticancer drug (DOX) should reach a minimum threshold to kill the cancer 
cells. In the MC paradigm, this can be considered as a reception mechanism where the intracellular concentra-
tion is the received signal, while the death of cancer cells is the output response.
In this model, a millimeter-scale dual-release implant, loaded with anticancer DOX drug, is assumed to be 
inserted inside a solid tumor to releases DOX anticancer agents. Here, we consider two solid tumor models, 
namely, thermally ablated and non-ablated tumors, surrounded by normal tissues. We consider the impact of the 
following factors on the drug transport process in tumor and surrounding normal tissue: interstitial fluid pressure 
and velocity, binding of DOX with albumin-proteins in the interstitial extracellular space, cellular influx/efflux of 
DOX across the cellular membranes, elimination of DOX into the blood and lymphatic microvessels. Impacts of 
all the above-mentioned pharmacokinetic processes are included in the drug transport model for predicting the 
extracellular and intracellular concentrations of both free and bound DOX. Furthermore, this model enables esti-
mate the toxicity of DOX on tumor cells and surrounding healthy tissue. The impact of DOX on the cancer cells 
is evaluated using a pharmacodynamic model that depends on the spatiotemporal intracellular concentration 
of DOX as well as on the characteristics of both the DOX and tumor cells. Moreover, the concentration of DOX 
in normal tissue is evaluated, which can be used for toxicity assessment. Accuracy and validity of our proposed 
model are verified and compared with the published experimental data in the literature, assuming the impact 
of the various pharmacokinetic parameters are combined in the apparent diffusivity and apparent elimination 
constant. To the best of our knowledge, this work is the first comprehensive model available in the literature that 
simultaneously captures and addresses the anticancer drug transport, pharmacokinetics, and pharmacodynamics 
using local dual-release drug implants in malignant solid tumors following thermal ablation.
Results and discussion
In this study, the governing mathematical equations which describe the proposed model are discretized in space 
with the finite element method using the commercial software package COMSOL Multiphysics 5.3. In COM-
SOL Multiphysics, we solve the interstitial fluid flow and drug transport models together with the tumor cell 
density model. The steady-state solutions of the interstitial velocity and pressure fields are applied to the drug 
transport model. Both the fluid flow and the drug transport models are solved under relative tolerance of  10–6 
and absolute tolerance  10–7. The numerical computation is run to examine the model over a timeframe of 4 days 
(96 h), assuming the initial time is the time of insertion of the implant in the tumor. In this model, the tumor 
characteristics and the drug parameters are taken from the published experimental works and other studies in 
the literature. The parameters used in this study are given in  Tables 2, 3, 4 and 5.
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As shown in Fig. 3, the average and maximum interstitial fluid pressure (IFP) in the tumor are equal to 
1466 Pa and 1533 Pa, respectively. However, the average pressure in the normal tissue is equal to 50 Pa, which is 
significantly lower than the pressure in the tumor. Furthermore, there is a sharp pressure gradient (and conse-
quently, high-velocity field) at the interface boundary between the tumor and normal tissues, as shown in Fig. 3. 
This result is not surprising due to the lake of the lymph vasculature in the tumor compared to the normal tissue. 
The trend of the results agrees well with the previous studies in the  literature1,27,28.
A group of researchers conducted experiments for measuring the DOX concentration with the distance from 
polymer implants placed inside thermally ablated liver  tumor8,20,21,29. In Fig. 4, we verify the accuracy and validity 
of our drug transport model by comparing the results with the published experimental  data21. The impact of the 
various processes in the tumor, including the binding effect, is given in terms of the apparent elimination rate 
constant and apparent  diffusivity20. The parameters used in this comparison are chosen to be the same as that 
used in the  experiment21. The apparent diffusivity of DOX in the liver tumor is given as D = 50 µm2/s while it 
varies within the thermally ablated tumor; thus, we use an average  value20 of 78.2 µm2/s. The apparent elimina-
tion rate constant of DOX in the liver tumor is γ = 0.58 × 10–4 s−1, and it is negligible in the ablated tumor within 
the first 4  days20, i.e., γ = 0 s−1. As expected, the measured concentration shows a decreasing trend with the radial 
distance from the implant. The results obtained using our numerical COMSOL model agree well with the results 
extracted from the published experimental data. This indicates the accuracy and validity of the drug release and 
transport model, which represents the main part of the proposed model in this paper.
In this study, the concentration distribution profiles for both 80% and 90% ablation have a similar trend 
with the time and distance but with slightly different amplitudes. Therefore, we do not show all the results in 
this paper to eliminate the redundancy. Figure 5 shows the spatial-mean extracellular concentration profiles of 
free-DOX and bound-DOX in the risk region of 90% ablated tumor. The implant with a higher release rate leads 
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Figure 3.  (a) Interstitial fluid pressure and (b) velocity field in the tumor and normal tissues with the radial 
distance from the tumor center.
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Figure 4.  Comparison of DOX concentration obtained from the experimental  data21 with our models using 
apparent diffusivity and apparent elimination rate.
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to a larger peak concentration and lower peak time. As the release rate increases, the amount of the released 
DOX will increase rapidly, and thus the peak concentration will reach a higher value within a shorter time. The 
increasing and decreasing rates of the extracellular concentration become sharper as the release rate constant 
increases. The decay in concentration after it reaches the peak value is due to a reduction in the released drug 
from the implant and elimination through blood vessels and cellular uptake. The bound-DOX concentration has 
a similar trend as the free-DOX concentration for various sustained release rate constants but with approximately 
three-fold higher amplitude.
Figure 6 shows the extracellular free-DOX concentration versus the distance from the implant/tissue interface 
in ablated and non-ablated solid tumors. The extracellular DOX concentration in a solid tumor without apply-
ing thermal ablation has a smaller amplitude than the concentration in an ablated tumor. This happens because 
in the non-ablated tumor, the cells and blood vasculature structures, which cover a large volume of the solid 
tumor, have a high impact on the elimination of the DOX through the cellular uptake and the blood microvessels. 




































































































Figure 5.  Spatial-mean temporal concentration profile of (a) free-DOX and (b) bound-DOX in the 
extracellular space of the risk region in 90% ablated tumor.
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Figure 6.  Spatial extracellular concentration of free-DOX at t = 96 h (fourth day), after insertion of the implant 
in a solid tumor with/without RFA.
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Furthermore, the drug can penetrate a larger distance and cover a larger volume in the ablated tumor compared 
to the non-ablated tumor. Also, tumor with larger ablation radius (e.g., 90%) shows higher DOX concentration 
and larger penetration compared to smaller ablation radius (e.g., 80%) on the fourth day as shown in Fig. 6. The 
observed impact of the thermal ablation on the drug distribution in tumors agrees with the experimental data 
in the  literature6,8,21.
The intracellular concentration of free-DOX in the risk region of 90% ablated tumor is shown in Fig. 7. The 
DOX intracellular concentration follows a similar trend as the extracellular concentration because it highly 
depends on the extracellular DOX levels. The higher peak amplitude of the intracellular concentration can be 
achieved using a faster release implant. As shown in Fig. 7b, the intracellular concentration decreases as the 
distance increases from the inner boundary of the risk region. This happens because the extracellular DOX con-
centration decreases with the distance, and it has a direct influence on the intracellular uptake and, consequently, 
on the intracellular DOX concentration.
Figure 8 shows the tumor cell density in the risk region with the radial distance from the inner boundary of 
the risk region of 80% ablated tumors at various times following the insertion of the implant. Tumor cell density 
shows heterogeneous distribution along the radial direction, where it increases with the distance with minimum 
density appears near the inner boundary of the risk region. This can also be seen in the color map of the spatial 
distribution of tumor cell density in Fig. 10. Moreover, there is a significant reduction in tumor cell density over 
time following the insertion of the implant. Furthermore, we found that the implant with the release rate con-
stants  ks = {5, 25} × 10–6 s−1 will almost have the same therapeutic effect on the last day of treatment. However, 
using a smaller release rate will consume less amount of the drug with minimum toxicity on the normal tissue. 
Therefore, design the implant with an optimal release rate is very important to get a high therapeutic efficacy.
The final therapeutic outcomes of the combination therapy using the DOX-loaded implant and RFA can be 
obtained from the tumor survival curves, as shown in Fig. 9. We can see that using the implant alone for tumor 
treatment without RFA leads to a negligible impact on the tumor cell density, even with a high release rate, i.e., 
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Figure 7.  Intracellular free-DOX concentration in the risk region of 90% ablated tumor for various release rate 
constants (a) spatial-mean temporal concentration profile and (b) spatial concentration at t = 12 h.
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90% of the tumor cells survive at the end of the treatment (at t = 96 h). In the case of 80% ablated tumor, there 
is about 40% cancer cells survive on the last day of the treatment. However, for 90% ablated tumor, most of the 
tumor cells are killed on the last day, i.e., only 4% survival cells. This can also be confirmed in the color map 
of tumor cell distribution, as shown in Fig. 10. Thus, the combination treatment using the implant following 
RFA will result in high therapeutic efficacy in destroying the residual tumor cells compared to a single therapy 
approach. Moreover, the release rate constants,  ks = {5, 25} × 10−6 s−1, show a similar therapeutic effect on the last 
day (at t = 96 h) with lower tumor survival compared to an implant with  ks = 1 × 10−6 s−1.
In general, the IDDSs have negligible toxicity on the surrounding healthy tissue and do not cause systemic 
toxicity. However, the amount of DOX which may reach to the normal tissue should be minimized to reduce the 
toxicity risks. The DOX level in the normal tissue can be used as a metric to predict the toxicity. In this study, 
the peak DOX concentration in normal tissue under all the examined release rates, as listed in Table 1, is found 
to be lower than the half-maximal inhibitory  concentration27  (IC50 = 4.13 × 10−5 kg/m3). The peak extracellular 
concentration of free and bound-DOX in the solid tumor without RFA has very small and negligible values. In 
the non-ablated solid tumor, the released DOX from the implant will be affected by the cellular uptake and the 






































Figure 9.  The survival fraction of tumor cells in non-ablated and ablated tumors for various sustained release 
rate constants.
Figure 10.  Cross-sectional view of the spatial distribution of tumor cell density in the risk region at different 
times for (a) 90% ablated tumor, (b) 80% ablated tumor, and (c) tumor without RFA when ks = 5 × 10−6 s−1.
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elimination through the blood vessels before reaching the normal tissue. This explains why the amount of DOX 
that appears in the normal tissue is very small in the case of the non-ablated tumor compared to the ablated 
tumor where the vascular and cellular structures are destroyed.
Conclusions
In this paper, we propose comprehensive mathematical and computational models for the transport of antican-
cer drug following the insertion of a dual-release implant in thermally ablated solid tumor with the help of the 
molecular communication paradigm. We predict the extracellular and intracellular concentrations of both free 
and bound-DOX in the various regions of thermally ablated solid tumor. This model includes the impact of the 
various pharmacokinetic processes such as binding of DOX to proteins, cellular influx/efflux, and elimination into 
the vasculature system. Also, we investigate the impact of the pressure and velocity of interstitial fluid on DOX 
transport in tumor and surrounding healthy tissue. Accuracy and validity of the proposed transport model is 
verified with the published experimental data assuming that the various pharmacokinetic processes are combined 
in the apparent diffusivity and elimination constant. Moreover, we examine the impact of the anticancer drug on 
tumor cell density, which shows a significant reduction in cell density over time. The combination therapy using 
the implantable drug delivery following thermal ablation results in high therapeutic efficacy. We found that the 
anticancer drug does not lead to toxicity effect on the normal tissue. The proposed model can help to optimize 
the development of the combination technique for treating solid tumors. Thus, we can reduce the clinical trials 
and the number of animals in biomedical research to save time and reduce cost. One of the limitations in our 
model is ignoring the impact of the implant biodegradation and drug interactions with the tissue surround-
ing the implant on the drug release process. Another limitation is using average diffusivity within the ablated 
tumor. However, the diffusivity varies with the radial distance in the ablated tumor. We will improve our model 
to overcome these limitations in future works.
Method
Mathematical model. Solid tumors are heterogeneous environments due to spatial heterogeneity of the 
tumor vasculature and the cells. However, due to the unavailability of experimental heterogeneity data of solid 
tumors and to simplify the analysis, the solid tumors are widely treated in the literature as spatially homogene-
ous  media27,28,30–32. Thus, we do not discriminate between the necrotic and viable tumor regions. Moreover, 
we assume that the growth timescale of the tumor and normal tissues is much longer than the timescale of the 
transport phenomena and the observation time window. Thus, it would be reasonable to assume that the system’s 
physiological parameters to be time-independent27. Incomplete radiofrequency ablation (RFA) will create an 
ablated zone, with no viable cancer cells, surrounded by a tumor rim (risk region) that shows a high density of 
the viable malignant cells, as shown in Fig. 11.
Tumor microenvironment modelling. Interstitial fluid transport. The tumor and surrounding tissue 
can be treated as porous media because the length scale of the intercapillary distances is much smaller than the 
tumor  radius27,30,33,34. Thus, the variations over the microscopic length scales can be averaged out, and the inter-
stitial fluid flow (IFF) is defined by coupling mass and momentum conservation equations.
For incompressible Newtonian fluid flow through a porous medium, the momentum conservation equation 
(Navier–Stokes equation) is simplified to Darcy’s law at a steady-state, which is quite applicable to the analysis of 
the interstitial fluid  flow33. Darcy’s law is used to account for the convective contribution of the interstitial fluid 
through porous media. Darcy law is derived for incompressible Newtonian fluid with neglecting the following 
factors: the divergence of the velocity, the inertial force, and the friction within the fluid and between the fluid 
and solid phases. Similar to other works in the  literature35,36, the fluid flow in the tumor tissue with thermal 
ablation can be modelled using Darcy law.
where vi is the interstitial velocity field (IVF) in (m/s), Pi is the interstitial fluid pressure (IFP) in (Pa), ki is the 
hydraulic conductivity of the interstitial fluid in (m2/(Pa s)).
The mass continuity (balance) equation for an incompressible fluid in the porous media with source and sink 
of mass is given as  follows27.
(1)�vi = −ki∇Pi
Table 1.  The maximum DOX concentration in the normal tissue for ablated and non-ablated tumors.
Tumor Drug
Release rate constant
ks = 1 × 10–6 s−1 ks = 5 × 10–6 s−1 ks = 25 × 10–6 s−1
90% ablation
Free 58.9 × 10–8 202 × 10–8 430 × 10–8
Bound 176 × 10–8 608 × 10–8 1280 × 10–8
80% ablation
Free 0.28 × 10–8 0.99 × 10–8 2.04 × 10–8
Bound 0.85 × 10–8 2.98 × 10–8 6.13 × 10–8
No ablation
Free 0.72 × 10–12 0.74 × 10–12 1.10 × 10–12
Bound 2.16 × 10–12 2.21 × 10–12 3.32 × 10–12
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where ρi is the interstitial fluid density in (kg/m3), φvi is the mass fluid source term which represents the fluid flow 
rate per unit volume of tissue from the blood vessels into the interstitial space in (1/s), and φli is the lymphatic 
drainage (sink) term that represents the fluid flow rate per unit volume of tissue from the interstitial space into 
the lymph vessels in (1/s). The Eq. (2) is applicable to both normal and cancerous biological tissues.
The mass fluid source term φvi is governed by Starling’s  law27,30 as
where Pvi is the intervascular blood pressure (IBP) in (Pa), πvi is the osmotic pressure of the plasma in (Pa), πi 
is the osmotic pressure of the interstitial fluid in (Pa), Lvi is the hydraulic conductivity of the blood vessel walls 
in (m/Pa s), σi is the average osmotic reflection coefficient for plasma proteins, and Svi
/
Vi is the surface area of 
the blood vessels per unit volume of tissue in (1/m).
The lymphatic drainage term φli is given  as27,30
where Pli is the hydrostatic pressure of intra-lymphatic in (Pa), Ll is the hydraulic conductivity of the lymphatic 
wall in (m/(Pa s)), Sli
/
Vi is the surface area of the lymphatic vessels per unit volume of tissue in (1/m), and LlSl
/
V  
is the lymphatic filtration coefficient in (1/(Pa s)).
At steady state, the mass continuity equation for incompressible flow in porous media reduces to
Now, by combining Darcy’s law (1) and the mass continuity Eq. (5), we get
where ∇2 is the Laplacian operator.
The lymphatic drainage term is equal to zero in the tumor region due to the lake of the lymphatic system. 
Moreover, the mass fluid source term is equal to zero in the ablated-tumor region because the thermal ablation 
destroys the vascular network. Thus, Eq. (6) can be rewritten as
Equation (7), together with the boundary conditions (23)–(34), can be solved analytically or numerically. 
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two regions model, and thus we solve it using COMSOL Multiphysics software. The obtained interstitial fluid 
pressure and velocity will be used in the drug transport model in the next subsection.
Interstitial drug transport. In this model, the drug source is a miniaturized implant loaded with DOX antican-
cer drug inserted inside a solid tumor. The implant will release the anticancer drug, which diffuses through the 
surrounding tissue, and it will be influenced by the various pharmacokinetic processes, including drug efflux/
influx into cells, drug binding/unbinding with interstitial proteins, elimination into blood capillaries, and bio-
degradation. These factors have a significant impact on drug transport and therapeutic efficacy.
Transport of free-DOX in the interstitial space can be mathematically modelled using the following diffu-
sion–convection–reaction equation.
where ∇ is the Del gradient operator and the index i ∈ {a, t, n} refers to the ablated tumor, the non-ablated 
tumor, and the normal tissues. The function Cexi is the spatiotemporal extracellular concentration of free-DOX 
in the interstitial space in (g/m3), and DFi is the diffusion coefficient of free-DOX, which has a different value 
in each region.
The loss rate of free-DOX due to drainage in the lymphatic vessels and elimination by the blood capillaries.
The loss rate of free-DOX due to lymphatic drainage (φli) is given by Eq. (4). Since lack of lymphatic system in 
the tumor  region1,28,30, we set the loss rate due to lymphatic drainage equal to zero in both the ablated and non-
ablated tumor regions. Moreover, the experimental studies showed that thermal ablation destroys the vascular 
structure inside the ablated tumor zone, and therefore the DOX loss into the blood in this region is neglected. 
However, several blood microvessels may appear in the peripheral region of the ablation  zone37. Moreover, the 
initial concentration of DOX in the plasma is assumed to be zero, where the implant is the only drug  source38.
The loss rate of free-DOX due to elimination by blood vessels (γvi) can be expressed as  follows38,39.
where PFi is the permeability coefficient of the blood vessel wall to free-DOX in (m/s).
The term FB accounts for the binding and unbinding of DOX with Albumin proteins in the interstitial space.
where ka and kd are the DOX-protein association and dissociation reaction rates, respectively, and Cbi is the 
spatiotemporal bound-DOX concertation in the tissues.
The doxorubicin molecules can transport to/from the interior of the cell across the cell membrane. Thus, the 
effect of cellular uptake (influx) and efflux is modelled using the following cellular influx/efflux rate:
where Dc is the cancer cells density in the unit of  (105 cells/m3). The cellular influx and efflux functions, ζinf  and 
ζeff  , are given in Eqs. (14) and (15), respectively.
Modelling of the target cells. Drug absorption by the cells. The doxorubicin can transport across the 
cell membrane via passive diffusion and carrier-mediated  transport40. Free and bound DOX can cross the tumor 
cell membrane. The amount of bound DOX which enter the cells is  neglected41. Therefore, we assume that only 
free-DOX can uptake by the cells, and therefore the intracellular concentration is a function of the extracellular 
free-DOX concentration. The intracellular DOX concentration Cc is expressed in the unit of (ng/105 cells), and 
it changes with the time according to the following  equations42,43.
where ζinf and ζeff  are the cellular influx and efflux functions, Vmax is the maximum rate of transmembrane trans-
port, and φe is the extracellular volume fraction. The parameters Vmax , ke , and kc were obtained in the  literature43, 
by the fitting of the experimental data of intracellular Adriamycin concentration in tumor  cells44. The parameters 
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Albumin is moving protein molecules that can be found in the bloodstream and interstitial space. Some 
free-DOX molecules may bind to proteins, such as Albumin, in the interstitial space, then new macromolecules 
(bound-DOX) will be created. The bound-DOX may unbind from the DOX-protein complexes and then becomes 
free. The spatiotemporal transport of bound-DOX in the extracellular space can be modelled using the following 
diffusion–convection–reaction  equation27,41:
where Cexi is the spatiotemporal extracellular concentration of bound-DOX in the interstitial space and DBi is 
the diffusion coefficient of bound-DOX, which has a different value in each region.
The loss rate of bound-DOX due to the blood and lymphatic microvessels is given as
where PBi is the permeability coefficient of the blood vessel wall to bound-DOX.
Death of the tumor cells. The cancer cell density can be described using the following equations, which include 
the impact of the free-DOX concentration and the natural growth and death of  cells27,42.
where kgr and kdr are the natural growth and decay rate constants of the tumor cells, respectively, and km is the 
saturation constant. The nonlinear function K reflects the effect of the anticancer drug, which depends on the 
intracellular concentration of free-DOX, the maximal DOX cell killing rate ( kmax ), and Michaelis constant EC50 . 
Initial tumor cell density is used as an initial condition for solving Eq. (18). The parameters mentioned above 
are listed in Table 2.
Drug implant model. In this study, the drug implant is loaded with anticancer drug DOX. The main design 
parameters of the implant are the release rate, the implant size, and the amount of loaded drug. The release rate 
depends on the implant formation and the physicochemical properties of the loaded drug, which can be adjusted 
during the design phase by selecting appropriate materials, e.g., polymer and  drugs48. The optimal release rate 
can help in improving the therapeutic outcomes by reducing the side effects, which in order save time and cost. 
The amount of the released drug can be experimentally monitored over time to obtain the release profiles. Rel-
evant mathematical models for the release kinetic can be fitted to the experimentally measured release curves to 
predict the release rate  constants49. The implant has a dual-release pattern, i.e., it releases DOX over two phases: 
fast burst release over a short time duration followed by slow sustained release over an extended period of time. 
Thus, we can model both dual-release and sustained release implants by adjusting the release parameters. For 
example, in-situ forming implants (ISFIs) and double-layer implants have dual-release  pattern6,12.
The cumulative amount of released DOX at the time t can be mathematically modelled using the bi-expo-





























Table 2.  Tumor cell density and intracellular concentration parameters.
Parameter Unit Value References
Vmax ng/(s  105 cells) 4.67 × 10−3 27,41–43,45,46
ke kg/m3 2.19 × 10−4 27,41–43,45,46
kc ng/105 cells 1.37 27,41–43,45,46
φe – 0.4 27,41,43,45
Dc0 105 cells/m3 1 × 1010 27,41,42,45,46
kgr s−1 5.78 × 10−6 42,46
kdr s−1 2.78 × 10−6 42,46
km m3/(s  105 cells) 3 × 10−16 27,42,46
kmax s−1 1.67 × 10−5 27,47
EC50 ng/105 cells 0.5 27,47
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where M0 is the total amount of loaded-drug in the implant in (mg), W∞ is the total fraction of drug released at 
steady state, and f is a fraction of drug released during the burst phase. The parameters kf  and ks are release rate 
constants for burst and sustained release phases in  (s−1), respectively.
Now, the rate of drug release across the spherical implant surface at time t per unit area of the implant surface 
in g/(s  m2), i.e., the flux, can be expressed as
where A = 4πr20 is the surface area of the implant and r0 is the implant radius.
The characteristic parameters of the dual-release implant are listed in Table 3. Similar to the experimental 
release  data6, we chose 10% of the loaded drug to be released within the first hour while different values of 
sustained-release rate constant are examined.
The experimental studies in the literature showed insignificant variation for the size of the implant during 
the release duration since the implant releases drug prior to any significant  degradation38. Thus, it is reasonable 
to assume that the size variation due to biodegradation is negligible during the observation  time6,38.
Model parametrization. In this work, the values of the model parameters are obtained from the published 
experimental data and other studies in the literature, assuming that the growth of the tissues is negligible dur-
ing the observation timeframe. This assumption is widely used in the literature since the time scales of fluid and 
drug transport phenomena are relatively  short27. Thus, it would be reasonable to assume that the system’s physi-
ological parameters to be time-independent. The parameters are defined through the paper and summarized in 
Tables 2, 3, 4 and 5.
Microvasculature density (S/V). The microvasculature density is the ratio of vascular surface area per unit vol-
ume of tissue. The microvasculature density of capillaries highly varies among tumor types and within the same 
type of  tumor34. However, the experimental data show a leak of lymph vessels in the tumor tissues. Different 
studies show that the larger tumors have smaller microvasculature  densities34,50. For a tumor with 2 cm diameter 
(i.e., volume = 4188  mm3), the surface area of the blood vessels per unit volume of tumor tissue is approximately 
equal to  104 1/m34. In normal tissues, the surface area of the blood vessels per unit volume of tissue is measured 
as 7 × 103 1/m51. As mentioned before, the histological analysis confirms that the thermal ablation destroys the 
vascular network and tumor cells in ablated tumor  tissue4,8,12,21,52–54. Thus, the effect of microvasculature density 


















Table 3.  The dual-release implant parameters.
Parameter Value Unit
M0 5 mg
kf 5 × 10–4 s−1




Table 4.  Fluid transport parameters.
Parameter Unit Tumor tissue Normal tissue References
πi Pa 2000 1333 27,28,30,32,55–57
πvi Pa 2666 2666 27,28,30,32,55–57
ρi kg/m3 1000 1000 27,32
µi Pa s 7.8 × 10−4 7.8 × 10−4 27,32
ki m2/(Pa s) 3.10 × 10−14 6.40 × 10−15 27,28,30,32,55–57
Svi
/
Vi m−1 10,000 7000 27,28,30,32,34,51,55–58
Lvi m/(Pa s) 2.10 × 10−11 2.70 × 10−12 27,28,30,32,55–57
LlSl
/
V 1/(Pa s) 0 4.17 × 10−7 27,30
Pli Pa 0 0 27,30
Pvi Pa 2080 2080 27,28,30,32,55–57
σi – 0.82 0.91 27,28,30,32,55–57
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Extracellular space fraction (φe). The volume fraction of extracellular space in the tumor is much larger than 
that in the normal tissue, and it ranges from 0.2 to 0.6 with tumor cell density ranges from 0.955–15.3  105 cells/
mm341. In this study, the volume fraction of extracellular space φe and the initial cell density Dc0 are chosen to be 
equal to 0.4 and 10 × 105 cells/mm3, respectively.
Microvasculature permeability  (PF,  PB). The vasculature permeability measures the capability of the blood or 
lymph microvessels to exchange various substances in and out of the vasculature. The vasculature permeability 
of Albumin (similar to Albumin bound-DOX) and free-DOX is approximately threefold higher in tumor than 
that in normal  tissues41.
Diffusion coefficients  (DF,  DB). The diffusivity of free-DOX is higher than Albumin-bound DOX, where the 
molecular weights (MW) of free-DOX and bound-DOX are 544 Da and 69 kDa, respectively. Moreover, the 
diffusivity of free and bound-DOX in the tumor is larger than that in normal tissues, as listed in Table 5. How-
ever, the experimental studies found that the diffusivity of DOX near the center of the ablated liver tumor after 
RFA, Dac , is 75% higher than that in non-ablated  tumor20,23. Based on the histological findings in ablated tumor 
tissues, the diffusivity shows dependency on the radial distance with a higher value at the center of the ablated 
tumor than the periphery region. The diffusion coefficient in the outer region of the ablated tumor ( rc ≤ r ≤ ra ) 
is characterized  as20,23
where ra is the ablation zone radius, rc = αra is the radius of the central region of the tumor, and α = 0.47.
The diffusivity Dac of the tumor center decreases linearly with the radial distance to finally reaches the dif-
fusivity of the non-ablated (risk) tumor, i.e., Dt . In this model, we use an average diffusion coefficient within 
the ablated liver tumor tissue. The mean diffusivity of the outer ablated region is calculated using the scale 
relationship of DOX diffusivity in ablated and non-ablated tissues, then by taking the average of the diffusivity 
given by Eq. (22).
Model geometry. In this work, a 3-D spherical solid tumor is considered with a diameter of 2 cm, as shown 
in Fig. 11. This value falls within the range of different tumor sizes encountered in  reality59, e.g., the diameter of 
tumors in rats and rabbits ranges from 0.5 to 2 cm. We examine three cases for the tumor microenvironment, 
namely, non-ablated tumor, 80% ablated tumor, and 90% ablated tumor. For example, 80% ablated tumor means 
that a tumor region of a radius ( 0.8× rt ) is ablated. In the case of the ablated tumor, a thin rim of viable cancer 
cells (risk region) will remain at the tumor periphery. The thickness of the risk regions with 80% and 90% abla-
tion zones are 2 mm and 1 mm, respectively. Here, the thickness of the normal region is chosen to be 5 mm. The 
implant has a radius of 1.5 mm, and it is located at the tumor center. The model geometry and mesh are created 
using a built-in CAD kernel in COMSOL Multiphysics package. The mesh size is chosen as “Finer” based on a 
convergence mesh independence test, which shows that a 5-times decrease in the mesh element size will pro-
vide a negligible enhancement, i.e., < 5%, in DOX concentration profiles. Moreover, we refined the mesh using 
“Boundary Layer Setting” at the implant/tissue boundary and other interface boundaries between the various 
regions, to handle the rapid change of drug concentration, velocity, and pressure at these interface layers.
Boundary conditions. Due to spherical symmetry, the pressure at the tumor center is characterized using 
no-flux boundary condition as
In this work, the observation time scale in the numerical analysis is assumed to be much shorter than the time 
scale for the growth of the tumor and normal  tissues27. Therefore, the interface boundary between the various 
regions are assumed to be fixed. The continuity boundary conditions of the interstitial pressure and fluid flux 
are imposed at these interface boundaries as





Table 5.  Free and bound doxorubicin parameters.
Parameter Unit Free Bound References
Da m2/s 5.34 × 10−10 13.95 × 10−12 Calculated according to the experimental  data20,23
Dt m2/s 3.40 × 10−10 8.89 × 10−12 27,32,41–43,45,46,60–62
Dn m2/s 1.58 × 10−10 4.17 × 10−12 27,32,41–43,45,46,60–62
ka s−1 0.833 – 27,41,42,45,46
kd s−1 – 0.278 27,41,42,45,46
Pt m/s 1 × 10−6 7.8 × 10−9 27,41,43,63
Pn m/s 3.33 × 10−7 2.6 × 10−9 27,41,43,63
MW kg/mol 0.544 69 27,32,43,45
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In addition, the outer boundary of the normal region is assumed to be fixed. The interstitial fluid pressure 
at this boundary has a minimal constant value. Thus, Dirichlet boundary condition can be applied at the outer 
boundary as
The total interstitial drug flux is a combination of diffusion and convection fluxes. In this model, the inter-
stitial velocity field mainly appears at the interface boundary between the tumor and the normal tissues due to 
a large pressure difference at that layer. The continuity boundary conditions of drug flux and concentration are 
applied at the interface boundaries between the various regions. The continuity boundary conditions are applied 
for both free and bound DOX as
where ∇ is the gradient operator in the spherical coordinate system and the index j is used to indicate either the 
free or bound DOX.
No flux (Neumann) boundary condition is applied at the outer boundary of the normal region as
The release process of DOX drug from the implant surface is modelled using the following flux boundary 
condition:
where Frs(t) is given by Eq. (21).
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